Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The trial will compare the effect on disease control and immunosuppression treatment of adding simvastatin 80mg once daily, over a follow-up and treatment period of 2 years. Patients will be randomised in a 1:1 fashion to standard treatment with placebo or standard treatment with the addition of simvastatin (80mg daily). They will be followed at 3 months intervals for 2 years with a primary end point of mean reduction in corticosteroid dosage at the 12 month follow-up visit.
Epistemonikos ID: a70ea62782fc7837ca546ac2181f9377ccd1f57e
First added on: May 12, 2024